TELA Bio (TELA) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached a record $19.0 million, up 26% year-over-year, driven by strong demand for OviTex and OviTex PRS, new customers, and international expansion.

• Net loss narrowed to $10.4 million from $11.0 million year-over-year, aided by a $7.6 million gain on the sale of the NIVIS product line.

• Gross margin was 68%, down from 69% in the prior year, mainly due to higher charges for excess and obsolete inventory.

• Strategic commercial and operational initiatives, including enhanced sales training, organizational streamlining, and efficiency improvements, contributed to improved productivity and are expected to reduce 2025 operating expenses by $5–10 million.

• Closed a public equity offering with $46.0 million in gross proceeds, strengthening liquidity.

Financial highlights

• Q3 2024 revenue: $19.0 million, up 26% year-over-year; OviTex unit sales grew 39% and OviTex PRS 44%.

• Gross profit for Q3 2024: $12.9 million (68% margin); operating expenses rose to $22.2 million from $20.6 million in Q3 2023.

• Net loss improved to $10.4 million from $11.0 million year-over-year; loss from operations was $9.4 million, down from $10.2 million.

• Cash and cash equivalents at quarter-end: $17.3 million; working capital: $27.3 million.

• Completed a $46.0 million public offering in October 2024, resulting in $43 million net proceeds.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $74.5–$76.5 million, representing 27–31% growth over 2023.

• Operating and net losses expected to be lower in 2024 than 2023, excluding the impact of the NIVIS divestiture.

• Operational improvements and cost-cutting measures are anticipated to reduce 2025 operating expenses by $5–10 million.

• Existing cash resources, including public offering proceeds, are expected to fund operations for at least the next 12 months.

• No meaningful impact detected yet from IV fluid shortages or elective procedure disruptions, but effects remain unpredictable.